The EPS beat is overshadowed by a clear revenue miss and heavy dilution from the Q1 offering. Watch for mid-2026 pipeline data readouts (casdozokitug, tagmokitug) as key catalysts; the $167M cash position provides runway but operating burn remains high at ~$58M/quarter.
CHRS drugs
CHRS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 12 $1.71entry
- T+1 · 6mo ago 0.00%α −0.54% · $1.71
- T+5 · 6mo ago −12.87%α −12.94% · $1.49
- T+20 · 5mo ago −20.47%α −18.74% · $1.36
- T+60 · 3mo ago −26.02%α −30.41% · $1.27
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14.3M estimate by 14.0%. LOQTORZI revenue grew 61% YoY to $11.8M, but total revenue was dragged lower than expected, and the company completed a dilutive $53.6M equity offering during the quarter.
Key Financial Metrics
Key Facts
- GAAP EPS from continuing operations: -$0.27 vs consensus -$0.29 (beat by 6.9%)
- Revenue: $12.3M vs consensus $14.3M (miss by 14.0%)
- LOQTORZI net product revenue: $11.8M, up 61% YoY from $7.3M
- Net loss from continuing operations improved to -$36.9M from -$47.4M YoY
- Cash, equivalents and marketable securities: $167.0M at quarter-end
- Completed public offering of 32.89M shares for net proceeds of $53.6M in Q1 2026
- Operating cash flow: -$57.9M in Q1 2026 vs -$25.8M in Q1 2025
- Pipeline catalysts: casdozokitug Phase 2 1L HCC data expected mid-2026; tagmokitug multiple readouts in 2026
Financial Impact
Revenue miss of $2.0M (14%) vs consensus; EPS beat of $0.02 (6.9%); $53.6M dilutive equity offering increased share count by ~31%
Risk Factors
- Revenue miss of 14% vs consensus signals weaker-than-expected LOQTORZI adoption
- Dilution of ~31% from Q1 equity offering pressures per-share metrics
- Operating cash burn of -$57.9M in Q1 2026, up from -$25.8M YoY
- Heavy reliance on pipeline data readouts for valuation inflection
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292299 |
Track record
15 reports on CHRS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
- Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
- Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
- Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
- Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
- May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
- May 11, 202627w ago Press Release Mixed 6/10 Viewing Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers